File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1186/s12890-024-02888-z
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Article: High-sensitivity C-reactive protein level in stable-state bronchiectasis predicts exacerbation risk
Title | High-sensitivity C-reactive protein level in stable-state bronchiectasis predicts exacerbation risk |
---|---|
Authors | |
Issue Date | 13-Feb-2024 |
Publisher | BioMed Central |
Citation | BMC Pulmonary Medicine, 2024, v. 24 How to Cite? |
Abstract | Background: Elevation of systemic inflammatory markers were found to correlate with increased disease extent, reduced lung function and higher risk of future severe exacerbations in patients with bronchiectasis. Although a significant correlation of circulating hs-CRP levels with HRCT scores and resting oxygen saturation in patients with stable-state non-cystic fibrosis (CF) bronchiectasis was suggested, there is little data on the relationship between hs-CRP and the prognosis of bronchiectasis and a lack of data on the role of hs-CRP in predicting bronchiectasis exacerbation. Methods: A prospective study was conducted on Chinese patients with non- CF bronchiectasis from 1st October to 31st December 2021. Baseline serum hs-CRP were obtained at stable-state. The follow-up period lasted for one year. Co-primary endpoints were the development of any bronchiectasis exacerbation and hospitalized bronchiectasis exacerbation. Results: Totally 123 patients were included. Higher hs-CRP was associated with increased risk to develop any bronchiectasis exacerbation, adjusted odds ratio (aOR) of 2.254 (95% CI = 1.040-4.885, p = 0.039), and borderline significantly increased hospitalized bronchiectasis exacerbation with aOR of 1.985 (95% CI = 0.922-4.277, p = 0.080). Conclusion: Baseline serum hs-CRP level at stable-state can predict risk of bronchiectasis exacerbation, which is reflecting chronic low-grade inflammation in bronchiectasis. |
Persistent Identifier | http://hdl.handle.net/10722/340033 |
ISSN | 2023 Impact Factor: 2.6 2023 SCImago Journal Rankings: 0.773 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwok, Wang Chun | - |
dc.contributor.author | Teo, Kay Cheong | - |
dc.contributor.author | Lau, Kui Kai | - |
dc.contributor.author | Ho, James Chung-man | - |
dc.date.accessioned | 2024-03-11T10:41:10Z | - |
dc.date.available | 2024-03-11T10:41:10Z | - |
dc.date.issued | 2024-02-13 | - |
dc.identifier.citation | BMC Pulmonary Medicine, 2024, v. 24 | - |
dc.identifier.issn | 1471-2466 | - |
dc.identifier.uri | http://hdl.handle.net/10722/340033 | - |
dc.description.abstract | <p><strong>Background: </strong>Elevation of systemic inflammatory markers were found to correlate with increased disease extent, reduced lung function and higher risk of future severe exacerbations in patients with bronchiectasis. Although a significant correlation of circulating hs-CRP levels with HRCT scores and resting oxygen saturation in patients with stable-state non-cystic fibrosis (CF) bronchiectasis was suggested, there is little data on the relationship between hs-CRP and the prognosis of bronchiectasis and a lack of data on the role of hs-CRP in predicting bronchiectasis exacerbation.</p><p><strong>Methods: </strong>A prospective study was conducted on Chinese patients with non- CF bronchiectasis from 1st October to 31st December 2021. Baseline serum hs-CRP were obtained at stable-state. The follow-up period lasted for one year. Co-primary endpoints were the development of any bronchiectasis exacerbation and hospitalized bronchiectasis exacerbation.</p><p><strong>Results: </strong>Totally 123 patients were included. Higher hs-CRP was associated with increased risk to develop any bronchiectasis exacerbation, adjusted odds ratio (aOR) of 2.254 (95% CI = 1.040-4.885, p = 0.039), and borderline significantly increased hospitalized bronchiectasis exacerbation with aOR of 1.985 (95% CI = 0.922-4.277, p = 0.080).</p><p><strong>Conclusion: </strong>Baseline serum hs-CRP level at stable-state can predict risk of bronchiectasis exacerbation, which is reflecting chronic low-grade inflammation in bronchiectasis.</p> | - |
dc.language | eng | - |
dc.publisher | BioMed Central | - |
dc.relation.ispartof | BMC Pulmonary Medicine | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.title | High-sensitivity C-reactive protein level in stable-state bronchiectasis predicts exacerbation risk | - |
dc.type | Article | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1186/s12890-024-02888-z | - |
dc.identifier.volume | 24 | - |
dc.identifier.eissn | 1471-2466 | - |
dc.identifier.issnl | 1471-2466 | - |